Safe and Affordable Drugs from Canada Act of 2024
Latest Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Safe and Affordable Drugs from Canada Act of 2024 (S.4918) is a Senate bill introduced in the 118th Congress aimed at addressing drug affordability by allowing the importation of prescription drugs from Canada. The bill was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions but ultimately failed or expired without further legislative action. No official summary or full text is available, limiting detailed analysis of specific provisions.
This bill sought to enable access to lower-cost prescription drugs from Canada but did not advance beyond committee referral and expired in the 118th Congress.
- Introduced in the Senate during the 118th Congress as S.4918.
- Focused on health policy, specifically drug affordability through importation from Canada.
- Referred to the Senate Committee on Health, Education, Labor, and Pensions but did not progress.
- No official summary or full bill text is publicly available.
- Status is recorded as failed or expired.
['U.S. patients seeking more affordable prescription medications', 'Healthcare providers and pharmacies potentially facilitating access to imported drugs', 'Potentially Canadian pharmaceutical suppliers involved in export']
['Lack of publicly available full bill text limits clarity on implementation mechanisms and regulatory oversight.', 'Potential challenges in ensuring drug safety and quality standards for imported medications.', 'Unclear funding or enforcement provisions due to missing bill text.', 'Possible trade or regulatory conflicts between U.S. and Canadian authorities.']
The bill was introduced in the Senate during the 118th Congress and referred to the Committee on Health, Education, Labor, and Pensions. It did not advance beyond committee referral and expired, reflecting challenges in legislative progress on drug importation policies. The absence of an official summary or full text suggests limited public disclosure or debate on the bill's detailed provisions.
High concern review — 3 hidden impact flags detected
GovScope reviewed 3 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential reduction in U.S. drug prices if importation is enabled and supply is sufficient.', 'Possible impact on U.S. pharmaceutical market dynamics and pricing strategies.', 'Increased administrative burden on regulatory agencies to monitor imported drugs.', 'Cross-border trade relations between U.S. and Canada may be affected by drug import policies.']
The absence of the full bill text and official summary significantly limits transparency and public understanding of the bill's detailed provisions and potential impacts. Oversight bodies and stakeholders would require access to complete legislative language to evaluate implementation feasibility, regulatory responsibilities, and enforcement mechanisms. The bill's failure to progress beyond committee referral further restricts available information on legislative intent and debate.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.